Biopharmaceutical Industry
Alnylam’s RNA interference drug wins favour of FDA AdCom
Alnylam’s Onpattro received a recommendation from an FDA advisory committee panel for a cardiomyopathy label expansion.
Mirum expands rare disease portfolio with digestive disorder drugs
Codagenix pursues RSV vaccine development amid unexpected challenges
US announces first ten drugs up for Medicare price negotiation
Novaliq pursues EMA approval for dry eye disease drug
Celcuity teams up with Bayer for Phase Ib/II prostate cancer trial
